Vor Biopharma Inc.
VOR
$23.83
-$1.27-5.06%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 24.87% | 4.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 36.10% | -2.22% | |||
| Operating Income | -36.10% | 2.22% | |||
| Income Before Tax | 71.40% | -112.75% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 71.40% | -112.75% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 71.40% | -112.75% | |||
| EBIT | -36.10% | 2.22% | |||
| EBITDA | -36.11% | 2.24% | |||
| EPS Basic | 77.35% | -106.01% | |||
| Normalized Basic EPS | 77.34% | -106.03% | |||
| EPS Diluted | 77.35% | -106.01% | |||
| Normalized Diluted EPS | 77.34% | -106.03% | |||
| Average Basic Shares Outstanding | 26.26% | 111.92% | |||
| Average Diluted Shares Outstanding | 26.26% | 111.92% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||